Auner HW, Garderet L, Kröger N. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. Br J Haematol. 2015;171(4):453–62.
Article
Google Scholar
Rosenberg AS, Brunson A, Jonas BA, Keegan THM, Wun T. Association between autologous stem cell transplant and survival among californians with multiple myeloma. J Natl Cancer Inst. 2019;111(1). [cited 2020 Oct 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/29897481/.
Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 1997;20(6):445–50. [cited 2020 Oct 7] Available from: https://pubmed.ncbi.nlm.nih.gov/9313876/
Clemmons AB, Anderegg S. Mixed outpatient-inpatient autologous stem cell transplant for multiple myeloma: a cost-saving initiative in a resource constrained environment. J Oncol Pharm Pract. 2017;23(5):384–8. [cited 2020 Oct 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/27000280/.
Rondelli D, Kun TL, Mathews V, Gooneratne LV, Tuladhar S, Neupane S, et al. First Global Blood & Marrow Transplant [GlobalBMT] Conference in Kathmandu with experiences from Nepal, India, Singapore and Sri Lanka. J Glob Health. 2018;8(1):1–5.
Article
Google Scholar
Berro M, Arbelbide JA, Rivas MM, Basquiera AL, Ferini G, Vitriu A, et al. Hematopoietic cell transplantation–specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(10):1646–50. Available from: https://doi.org/10.1016/j.bbmt.2017.06.014.
Zweegman S, Engelhardt M, Larocca A. Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol. 2017;29:315–21.
Article
Google Scholar
Antoine-Pepeljugoski C, Braunstein MJ. Management of newly diagnosed elderly multiple myeloma patients. Curr Oncol Rep. 2019;21:1. [cited 2020 Oct 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/31127403/.
Marini C, Maia T, Bergantim R, Pires J, Aguiar E, Guimarães JE, et al. Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Ann Hematol. 2019;98(2):369–79. [cited 2020 Oct 7]. Available from: https://pubmed.ncbi.nlm.nih.gov/30368589/.
Dold SM, Möller MD, Ihrost G, Langer C, Pönisch W, Mügge LO, et al. Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica. 2021;106(3):875–80.
Article
Google Scholar
Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia. 2009;23(6):1131–8.
Article
CAS
Google Scholar
Martino M, Morabito F. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well. Expert Opin Biol Ther. 2015;15(2):149–54.
Article
CAS
Google Scholar
Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019;54(3):353–67. Available from: https://doi.org/10.1038/s41409-018-0264-8.
Article
CAS
Google Scholar
Fermand J-P, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23(36):9227–33. [cited 2020 Jul 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16275936.
Coriu D, Dytfeld D, Niepel D, Spicka I, Markuljak I, Mihaylov G, et al. Real-world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries. Polish Arch Intern Med. 2018;128(9):500–11. [cited 2020 Jul 16]. Available from: https://pubmed.ncbi.nlm.nih.gov/30057386/.
Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175(1):66–76. [cited 2020 Jul 16]. Available from: https://pubmed.ncbi.nlm.nih.gov/27291397/.
Nair CK, Selvaraj K, Raghavan V, A M, Shenoy PK, Kurup AR, et al. Limiting factors for autologous transplantation among transplant-eligible multiple myeloma patients: lesson from a Tertiary Cancer Centre in rural India. Leuk Res. 2019;83:106167. Available from: https://doi.org/10.1016/j.leukres.2019.106167
Jacob LA, Suresh Babu MC, Lakshmaiah KC, Govind Babu K, Lokanatha D, Rajeev LK, et al. Multiple myeloma: experience of an institute in limited resource setting. Indian J Cancer. 2017;54(1):340–2. [cited 2020 Jul 16]. Available from: https://pubmed.ncbi.nlm.nih.gov/29199718/.
Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44. https://doi.org/10.1038/s41408-019-0205-9.
Isaacs A, Fiala M, Tuchman S, Wildes TM. A comparison of three different approaches to defining frailty in older patients with multiple myeloma. J Geriatr Oncol. 2020;11:311–5.
Article
Google Scholar
Mccarthy AL, Peel NM, Gillespie KM, Berry R, Walpole E, Yates P, et al. Validation of a frailty index in older cancer patients with solid tumours. BMC Cancer. 2018;18:892.
Article
CAS
Google Scholar
Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, et al. Frailty assessment instruments: systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev. 2016;26:53–61.
Article
Google Scholar
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–74.
Article
CAS
Google Scholar
Shahjahan M, Alamo J, de Lima M, Khouri I, Gajewski J, Andersson B, et al. Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDS patients in first complete remission. Biol Blood Marrow Transplant. 2004;10(Suppl 1):S12–3.
Article
Google Scholar
Xhaard A, Porcher R, Chien JW, de Latour RP, Robin M, Ribaud P, et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia. 2008;22(11):2062–9. https://doi.org/10.1038/leu.2008.197.
Article
CAS
PubMed
PubMed Central
Google Scholar
Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910–21.
Article
Google Scholar
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.
Article
CAS
Google Scholar
Yanamandra U, Khattry N, Kumar S, Raje N, Jain A, Jagannath S, et al. Consensus in the management of multiple myeloma in india at myeloma state of the art 2016 conference. Indian J Hematol Blood Transfus. 2017;33(1):15–21.
Article
Google Scholar
Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013;19(11):1615–24. [cited 2020 Jul 16]. Available from: https://pubmed.ncbi.nlm.nih.gov/23939198/.
Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. 2015;50(2):209–15. [cited 2020 Jul 16]. Available from: https://pubmed.ncbi.nlm.nih.gov/25387088/.
Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, et al. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016;101(11):1398–406. [cited 2020 Jul 16]. Available from: https://pubmed.ncbi.nlm.nih.gov/27662018/.
Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114(3):600–7.
Article
CAS
Google Scholar
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–8. https://doi.org/10.1038/leu.2013.313.
Article
CAS
PubMed
Google Scholar
Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, et al. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Acta Haematol. 2014;132(2):211–9. https://doi.org/10.1159/000357394.
Article
PubMed
Google Scholar
Sharma SK, Choudhary D, Gupta N, Dhamija M, Khandelwal V, Kharya G, et al. Cost of hematopoietic stem cell transplantation in India. Mediterr J Hematol Infect Dis. 2014;6(1):e2014046.
Article
Google Scholar